公开(公告)号：US20170081400A1

公开(公告)日：2017-03-23

申请号：US15267213

申请日：2016-09-16

Applicant: Cephalon, Inc.

Inventor： Lynn Dorothy Poulton ,  Matthew Pollard ,  Anthony G. Doyle ,  Bridget Ann Cooksey ,  Vanya Pande ,  Adam William Clarke

IPC: C07K16/24

CPC classification number: C07K16/241 ,  A61K2039/505 ,  A61P11/06 ,  A61P37/06 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.

公开(公告)号：US20190106486A1

公开(公告)日：2019-04-11

申请号：US16164509

申请日：2018-10-18

Applicant: Cephalon, Inc.

Inventor： Lynn Dorothy Poulton ,  Matthew Pollard ,  Anthony G. Doyle ,  Bridget Ann Cooksey ,  Vanya Pande ,  Adam William Clarke

IPC: C07K16/24 ,  A61P11/06 ,  A61P37/06 ,  C07K16/28

Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.

公开(公告)号：US11267883B2

公开(公告)日：2022-03-08

申请号：US16471616

申请日：2017-12-21

Applicant: Cephalon, Inc.

Inventor： David Jose Simon Laine ,  Matthew Pollard ,  Anthony Gerard Doyle ,  Lynn Dorothy Poulton ,  Adam William Clarke

IPC: C07K16/24 ,  A61P37/00 ,  A61P3/00 ,  A61P29/02 ,  A61P1/00 ,  A61K39/00

Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.

公开(公告)号：US10138296B2

公开(公告)日：2018-11-27

申请号：US15267213

申请日：2016-09-16

Applicant: Cephalon, Inc.

Inventor： Lynn Dorothy Poulton ,  Matthew Pollard ,  Anthony G. Doyle ,  Bridget Ann Cooksey ,  Vanya Pande ,  Adam William Clarke

IPC: C07K16/24 ,  C12N5/10 ,  C12N15/10 ,  C12N15/13 ,  C12N15/63 ,  G01N33/53 ,  C07K16/28 ,  A61P37/06 ,  A61P11/06 ,  A61K39/00

Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.